Company: ARTL
Filing Date: 2025-10-01
Form Type: 424B5
Source: 0001640334-25-001763
Chunk: 24

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 424B5
Chunk 24
---
.40 
 (4.89 | ) |
|:-----------------------------------------------------------------------------------|:----|:--|------:|:--|
| Increase in net tangible book value per share attributable to this offering        |     | $ |  2.41 |   |
| As adjusted net tangible book value per share after giving effect to this offering |     | $ | (1.48 | ) |
| Dilution per share to new investors participating in this offering                 |     | $ | (3.85 | ) |

If the underwriter exercises the option to purchase up to 68,181 additional shares of common stock in full at the public offering price of $4.40 per share, our adjusted net tangible book value as of June 30, 2025, after giving effect to this offering, would have been approximately $(1.15) per share, representing an increase in net tangible book value of approximately $2.83 per share to existing security holders and immediate dilution in net tangible book value of approximately $(3.93) per share to investors participating in this offering.

The above discussion and table is based on 704,425 shares of our common stock outstanding as of June 30, 2025 (giving effect to the one-for-six reverse stock split of our common stock effected on June 13, 2025), and excludes as of that date:

·227,842 shares of our common stock issuable upon the exercise of options or restricted stock awards granted under our 2018 Equity Incentive Plan (the “2018 Plan”), with a weighted-average exercise price of $11.03 per share;

·23,315 shares of our common stock issuable upon the exercise of warrants, with a weighted-average exercise price of $67.50 per share issued prior to June 30, 2025;

·123,255 shares of common stock issuable upon the voluntary conversion of convertible notes issued in our May 2025 private placement;

·246,511 shares of common stock issuable upon the automatic conversion of convertible notes issued in our May 2025 private placement to warrants to purchase common stock, with an exercise price of $6.24 per share;

·55,300 shares of our common stock issuable upon the exercise of pre-funded warrants issued in our June 2025 private placement, with an exercise price of $0.001 per share;

·437,448 shares of our common stock issuable upon the exercise of warrants issued in our June 2025 private placement,